Chronopharmacodynamics and mechanisms of antitumor effect induced by erlotinib in xenograft-bearing nude mice

Biochemical and Biophysical Research Communications

Volumn 460, Issue 2, 2015, Pages 362-367

  Lin, Pingping ^a   An, Fengmei ^b   Xu, Xia ^b   Zhao, Liyan ^b   Liu, Liang ^a   Liu, Ning ^a   Wang, Peipei ^c   Liu, Jiao ^d   Wang, Le ^a   Li, Mingchun ^b  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b 401 Hospital of PLA   (China)

^c FUDAN UNIVERSITY   (China)

^d WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

Chronopharmacology; Circadian rhythms; Erlotinib; HCC827; NSCLC

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; QUINAZOLINE DERIVATIVE;

ANIMAL; BAGG ALBINO MOUSE; CIRCADIAN RHYTHM; FEMALE; METABOLISM; MOUSE; NUDE MOUSE; PHOSPHORYLATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CIRCADIAN RHYTHM; FEMALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84937965065     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.03.039     Document Type: Article

References (35)

1. Jacques Ferlay, Hai-Rim Shin, and Freddie Bray Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int. J. Cancer 27 2010 2893 2917
2. Ahmedin Jemal, Rebecca Siegel, and Elizabeth Ward Cancer statistics, 2008 CA Cancer J. Clin. 58 2008 71 96
3. L. Crino, W. Weder, and J. van Meerbeeck Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann. Oncol. 21 Suppl. 5 2010 103 105
4. W. Smith, and F.R. Khuri The care of the lung cancer patient in the 21st century: a new age Semin. Oncol. 31 2 Suppl. 4 2004 11 15
5. J.H. Schiller, D. Harrington, and C.P. Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N. Engl. J. Med. 346 2002 92 98
6. F. Fossella, J.R. Pereira, and J. von Pawel Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX326 study group J. Clin. Oncol. 21 2003 3016 3024
7. Julian R. Molina, Ping Yang, and Stephen D. Cassivi Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship Mayo Clin. Proc. 83 2008 584 594
8. Yongjun Guo, Jie Ma, and Xiaodong Lyu Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset BMC Cancer 14 2014 834
9. Barbara Melosky Review of EGFR TKIs in metastatic NSCLC, including ongoing trials Front. Oncol. 4 2014 244
10. M. Steins, M. Thomas, and M. Geißler Erlotinib recent results Cancer Res. 201 2014 109 123
11. John R. Goffin, and Kevin Zbuk Epidermal growth factor receptor: pathway, therapies, and pipeline Clin. Ther. 35 2013 1282 1303
12. Kristine Griffett, and Thomas P. Burris The mammalian clock and chronopharmacology Bioorg. Med. Chem. Lett. 23 2013 1929 1934
13. J. Sprouse Pharmacological modulation of circadian rhythms: a new drug target in psychotherapeutics Expert Opin. Ther. Targets 8 2004 25 38
14. Francis Lévi Chronotherapeutics: the relevance of timing in cancer therapy Cancer Causes Control 17 2006 611 621
15. Marie-Christine Mormont, and Francis Levi Cancer chronotherapy: principles, applications, and perspectives Cancer 97 2003 155 169
16. Michael H. Smolensky, and Nicholas A. Peppas Chronobiology, drug delivery, and chronotherapeutics Adv. Drug Deliv. Rev. 59 2007 828 851
17. Thomas Friess, Werner Scheuer, and Max Hasmann Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy Clin. Cancer Res. 11 2005 5300 5309
18. L.K. Zerbe, L.D. Dwyer-Nield, and J.M. Fritz Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice Cancer Chemother. Pharmacol. 62 2008 605 620
19. Solange Peters, Stefan Zimmermann, and Alex A. Adjei Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions Cancer Treat. Rev. 40 2014 917 926
20. H. Kitano, J.Y. Chung, and K. Ylaya Profiling of phospho-AKT, phospho-mTOR, phospho-MAPK and EGFR in non-small cell lung cancer J. Histochem. Cytochem. 62 2014 335 346
21. T. Hiroshi, H.O. Shigehiro, and Y. Tomoko Chronopharmacology of antitumor effect induced by interferon-β in tumor-bearing mice J. Pharmacol. Exp. Ther. 294 2000 746 752
22. K. Satoru, N. Hiroo, and K. Yukako Optimizing the dosing schedule of TNP-470 [O-(chloroacetylcarbamoyl) fumagillol] enhances its antitumor and antiangiogenic efficacies J. Pharmacol. Exp. Ther. 304 2003 669 674
23. N. Hiroo, T. Takako, and N. Mariko Basis for dosing time-dependent change in the anti-tumor effect of imtinib in mice Biochem. Pharmacol. 72 2006 1237 1245
24. Alba A. Brandes, Enrico Franceschi, and Alicia Tosoni Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments Clin. Cancer Res. 14 2008 957 960
25. Niels Reinmuth, Michael Meister, and Thomas Muley Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer Int. J. Cancer 119 2006 727 734
26. Hongbin Ji, Danan Li, and Liang Chen The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies Cancer Cell 9 2006 485 495
27. X. Sui, N. Kong, and M. Zhu Cotargeting EGFR and autophagy signaling: a novel therapeutic strategy for non-small-cell lung cancer Mol. Clin. Oncol. 2 2014 8 12
28. R. Sodella, D.W. Bell, and D.A. Haber Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 305 2004 1163 1167
29. J.G. Paez, P.A. Janne, and J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
30. Sean Tracy, Toru Mukohara, and Mark Hansen Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255 Cancer Res. 64 2004 7241 7244
31. Zhenfeng Zhang, Susumu Kobayashi, and Alain C. Borczuk Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells Carcinogenesis 31 2010 577 586
32. Mattia Lauriola, Yehoshua Enuka, and Amit Zeisel Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment Nat. Commun. 5 2014 5073
33. Daniel E. Zak, Haiping Hao, and Rajanikanth Vadigepalli Systems analysis of circadian time-dependent neuronal epidermal growth factor receptor signaling Genome Biol. 7 2006 R48
34. Wymke Ockenga, Sina Kühne, and Simone Bocksberger Epidermal growth factor receptor transactivation is required for mitogen-activated protein kinase activation by muscarinic acetylcholine receptors in HaCaT keratinocytes Int. J. Mol. Sci. 15 2014 21433 21454
35. M. Berg, and K. Soreide EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy Discov. Med. 14 2012 207 214